ACRS News and Press, Aclaris Therapeutics Inc. From 09/16/19

A Phase 3 clinical trial, THWART-2 , evaluating Aclaris Therapeutics' (NASDAQ: ACRS ) A-101 45% topical solution for the treatment of common warts met the primary endpoint of a statistically significant proportion of patients whose identified warts were clear at day 60 compared to vehicle (...

Highly statistically significant results at the primary endpoint - statistical significance seen as early as Day 29 Highly statistically significant results on all secondary efficacy endpoints WART-302 is the first of two Phase 3 pivotal trials for the NDA If approved, A-101 45% Topical...

Durect (NASDAQ: DRRX ) initiated with Overweight rating and $5 (201% upside) price target at Cantor Fitzgerald. More news on: DURECT Corporation, Ekso Bionics Holdings, Inc., Kadmon Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Based on a strategic review, Aclaris Therapeutics (NASDAQ: ACRS ) will restructure its operations, including a reduction in headcount of 86 positions. Key points: More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Completion of Strategic Review and Refocusing of Resources on Immuno-Inflammatory Development Pipeline Actively Seeking a Commercialization Partner for RHOFADE® (oxymetazoline hydrochloride) cream, 1% Actively Exploring Strategic Alternatives for Commercial Assets, Alopecia and...

Aclaris Therapeutics ( ACRS ) announced that it had obtained positive results for its phase 2 study using ATI-501 to treat patients with Alopecia areata. The trial met the primary and secondary endpoint of the study. I believe this creates a great buying opportunity because there are a...

Aclaris Therapeutics, Inc. (ACRS) Q2 2019 Earnings Conference Call August 8, 2019 5:00 PM ET Company Participants Kamil Ali-Jackson – Chief Legal Officer Neal Walker – President and Chief Executive Officer David Gordon – Chief Medical Officer Frank Ruffo &#...

Aclaris Therapeutics (NASDAQ: ACRS ): Q2 GAAP EPS of -$1.21 misses by $0.46 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Undertaking strategic review of commercial and R&D assets IND for ATI-450, an investigational compound and oral MK2 inhibitor, allowed by the FDA in May 2019, and first patient dosed in Phase 1 clinical trial in August 2019 RHOFADE ® (oxymetazoline hydrochloride) crea...

WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced it will report financial results for the second quarter 2019, Thursday, August 8 th ...